Spebrutinib (AVL-292)

Catalog No.S7173 Batch:S717302

Technical Data

Formula	C₂₂H₂₂FN₅O₃
Molecular Weight	423.44	CAS No.	1202757-89-8
Solubility (25°C)*	In vitro


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Biological Activity

Description

Spebrutinib (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

Targets

BTK ^[1]
(Cell-free assay)

<0.5 nM

In vitro

AVL-292 exhibits dose-dependent inhibition of Btk with EC50 of 8 nM and downstream BCR signaling components in Ramos cells. ^[1] AVL-292, by inhibiting BTK activities, further inhibits B cell proliferation with EC50 of 3 nM. ^[2]

In vivo

In a collagen-induced arthritis mouse model, AVL-292 (3- 30 mg/kg, p.o.) dose-dependently inhibits the clinical signs of inflammatory disease, including reduction in joint and paw swelling and visible redness of the affected paws. ^[2]

Features

Orally bioavailable BTK-selective inhibitor that has been tested in Phase I clinical trials for treatment of relapsed or refractory B-NHL, CLL and WM.

Protocol (from reference)

Kinase Assay:^{^[2]}	Procedures for BTK OMNIA Assay The Omnia continuous read assay is performed essentially as described by the vendor. The assay conditions are: 40 μM ATP (1X K_MATP), 10 μM Y5-Sox, and 10 nM BTK enzyme. Briefly, a substrate mix containing 1.13X ATP and the Y5 Sox substrate is first prepared in 1X Omnia Kinase Reaction Buffer (KRB) consisting of 20 mM Tris, pH 7.5, 5 mM MgCl₂, 1 mM EGTA, 5 mMβ-glycerophosphate, 5% glycerol, and 0.2 mM DTT. For IC50 measurements, 5 μL of enzyme are incubated with serially diluted (3-fold) compounds prepared in 50% DMSO in a Corning (#3574) 384-well, white, non-binding surface microtiter plate at 25°C for 30 min. Kinase reactions are started with the addition of 45 μL of the ATP/Y5 substrate mix and monitored at λex360/λem485 in a Synergy 4 plate reader for 60 minutes. Progress curves from each well are examined for linear reaction kinetics and fit statistics. Initial velocity from each reaction is determined from the slope of a plot of relative fluorescence units versus time and then plotted against inhibitor concentration to estimate IC50 using the Response, Variable Slope model in GraphPad Prism from GraphPad Software.
Cell Assay:^{^[2]}	Cell lines Human B cells Concentrations ~1000 nM Incubation Time 72 hours Method A suspension of resting purified naïve human B cells isolated by negative selection in RPMI is prepared at 0.4–0.5 × 10⁶ cells/ml. Cells are mixed together with α-human IgM (final concentration of 5 μg/ml in each well) and vehicle (dimethyl sulfoxide) or AVL-292 (final concentrations of 0.01, 0.1, 1.0, 10.0, 100.0, or 1000 nM per well) and seeded in a 96-well plate. Cells are incubated for 56 hours in a humidified incubator maintained at 37°C and 5% CO₂. ³H-Thymidine is added (final concentration of 1 μCi in each well) and cells are incubated overnight, harvested, and measured for ³H incorporation. Experiments are performed in triplicate.

Kinase Assay:^{^[2]}

Procedures for BTK OMNIA Assay
The Omnia continuous read assay is performed essentially as described by the vendor. The assay conditions are: 40 μM ATP (1X K_MATP), 10 μM Y5-Sox, and 10 nM BTK enzyme. Briefly, a substrate mix containing 1.13X ATP and the Y5 Sox substrate is first prepared in 1X Omnia Kinase Reaction Buffer (KRB) consisting of 20 mM Tris, pH 7.5, 5 mM MgCl₂, 1 mM EGTA, 5 mMβ-glycerophosphate, 5% glycerol, and 0.2 mM DTT. For IC50 measurements, 5 μL of enzyme are incubated with serially diluted (3-fold) compounds prepared in 50% DMSO in a Corning (#3574) 384-well, white, non-binding surface microtiter plate at 25°C for 30 min. Kinase reactions are started with the addition of 45 μL of the ATP/Y5 substrate mix and monitored at λex360/λem485 in a Synergy 4 plate reader for 60 minutes. Progress curves from each well are examined for linear reaction kinetics and fit statistics. Initial velocity from each reaction is determined from the slope of a plot of relative fluorescence units versus time and then plotted against inhibitor concentration to estimate IC50 using the Response, Variable Slope model in GraphPad Prism from GraphPad Software.

Cell Assay:^{^[2]}

Cell lines
Human B cells
Concentrations
~1000 nM
Incubation Time
72 hours
Method
A suspension of resting purified naïve human B cells isolated by negative selection in RPMI is prepared at 0.4–0.5 × 10⁶ cells/ml. Cells are mixed together with α-human IgM (final concentration of 5 μg/ml in each well) and vehicle (dimethyl sulfoxide) or AVL-292 (final concentrations of 0.01, 0.1, 1.0, 10.0, 100.0, or 1000 nM per well) and seeded in a 96-well plate. Cells are incubated for 56 hours in a humidified incubator maintained at 37°C and 5% CO₂. ³H-Thymidine is added (final concentration of 1 μCi in each well) and cells are incubated overnight, harvested, and measured for ³H incorporation. Experiments are performed in triplicate.

References

Customer Product Validation

: , , Allergy, 2017, 72(11):1666-1676

: , , J Biomol Screen, 2015, 20(7):876-886.

Selleck's Spebrutinib (AVL-292) has been cited by 12 publications

Surface-associated antigen induces permeabilization of primary mouse B-cells and lysosome exocytosis facilitating antigen uptake and presentation to T-cells [ Elife, 2021, 10e66984]	PubMed: 34704555
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function [ Am J Physiol Cell Physiol, 2021, 320(5):C902-C915]	PubMed: 33689480
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. [ Haematologica, 2020, 10.3324/haematol.2019.238154]	PubMed: 32139435
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK [ Elife, 2020, 9e60470]	PubMed: 33226337
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK [ Elife, 2020, 9e60470]	PubMed: 33226337
Effects of Inhibitors against Syk-BTK-PI3K Signaling on Platelet Function [ ScholarsArchive@OSU, 2020, None]	PubMed: None
Effects of Inhibitors against Syk-BTK-PI3K Signaling on Platelet Function [ ScholarsArchive@OSU, 2020, 51]	PubMed: N/A
Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease [ J Neuroimmune Pharmacol, 2019, 10.1007/s11481-019-09839-0]	PubMed: 30758770
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib [ Blood, 2018, 132(21):2260-2272]	PubMed: 30213872
BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. [Smiljkovic D, et al. Allergy, 2017, 10.1111/all.13166]	PubMed: 28328081

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.